---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-038020"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2024-12-20T23:59:59+00:00"
generated_at: "2026-05-29T00:20:37.902528+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Eton Pharma closes $22.5M Increlex acquisition; expands credit facility

## Summary
- Acquired Increlex (mecasermin) from Ipsen for $22.5M at closing plus $8.7M inventory; $2.5M due on first and second anniversaries.
- Credit facility with SWK expanded by $25.7M to $30M, maturity to 3 years, SOFR+6.75%; warrant for 289,736 shares at $5.32 issued.
- Increlex is the only FDA/EMA approved treatment for severe primary IGF-1 deficiency in pediatric patients aged 2+.
- U.S. available via AnovoRx specialty pharmacy; Eton to commercialize outside U.S. after 6-month transition.
- Additional inventory purchase obligation up to EUR 15.0 million over 30 months; transaction financed by cash and credit.

## SEC filing metadata
- accession: 0001437749-24-038020
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2024-12-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774924038020/0001437749-24-038020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774924038020/eton20241215_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-038020
- JSON: https://secwatch.observer/filing/0001437749-24-038020.json
- Plain text: https://secwatch.observer/filing/0001437749-24-038020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.